Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
Non-Small Cell Lung Cancer(NSCLC)
DRUG: WX-0593 Tablets
Major Pathologic Response (MPR) Rate, Major pathologic response (MPR) rate is defined as percentage of residual viable tumor cells histologically detected in the resected primary tumor after surgery â‰¤10%., At time of surgery
Pathologic Complete Response (pCR) Rate, Pathologic complete response (pCR) rate is defined as the percentage of participants with absence of residual tumor in lung and lymph nodes., At time of surgery|Resectability rate, Resectability rate is defined as the percentage of participants who were able to undergo surgery after neoadjuvant therapy., At time of surgery|R0 Resection rate, R0 Resection rate is defined as the percentage of participants who were able to undergo R0 Resection surgery after neoadjuvant therapy., At time of surgery|Objective Response Rate (ORR), Objective Response Rate (ORR) is defined as the percentage of participants who have a complete response (CR) or partial response (PR). Responses are according to RECIST 1.1 as assessed by investigator., Prior to surgery|Disease Control Rate (DCR), Disease Control Rate (DCR) is defined as the percentage of participants who have a best overall response of CR, PR, or stable disease (SD). Responses are according to RECIST 1.1 as assessed by investigator., Prior to surgery|Event-free survival (EFS), Event-free survival (EFS) is the length of time after initial administration the participant remains free of recurrence/progression or death, whatever the cause., 3 years postoperatively|Disease-free survival (DFS), Disease-free survival (DFS) is the length of time after surgical resection the participant remains free of recurrence/progression or death, whatever the cause., 3 years postoperatively|Overall Survival (OS), Overall Survival (OS) is the length of time after initial administration the participant remains alive., 3 years postoperatively
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).